Oral glycoprotein Ilb/IIa antagonists for unstable angina - Is there still a chance for the oral substances?

被引:4
作者
Darius, H [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Dept Med 2, D-55101 Mainz, Germany
关键词
unstable angina; oral glycoprotein IIb/IIIa antagonists; platelets; fibrinogen receptor;
D O I
10.1016/S0049-3848(01)00308-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The intravenous glycoprotein IIb/IIIa antagonists abciximab, tirofiban and eptifibatide are well accepted for the therapy of patients with unstable angina and/or as concomitant medication during coronary interventions. Despite the fact that these drugs are not used in all patients presenting with unstable angina during coronary interventions, the scientific evidence is overwhelming including the substantial reduction in mortality 3 years after utilisation of abciximab for coronary interventions in patients with unstable angina. In addition to these two indications, intravenous glycoprotein IIb/IIIa antagonists are currently being investigated for use in patients undergoing carotid artery interventions, peripheral arterial interventions and stroke, as well as adjunct therapy in patients undergoing fibrinolytic therapy during acute myocardial infarction. In contrast, the large trials being performed in patients with unstable angina and following coronary interventions using oral glycoprotein IIb/IIIa antagonists have been very disappointing. There were only minor therapeutic effects detectable, resulting in a slight reduction in ischemic cardiac events in some investigations, however, in all studies, there was a slight trend towards an increased mortality in the glycoprotein IIb/IIIa receptor-antagonist-treated group of patients. In meta-analysis, an approximately 35% relative increase in mortality has been calculated for patients being treated long term with the oral glycoprotein antagonists. The reason for this therapeutic failure is still unknown, however, the limited bioavailability of these drugs, together with our still very limited knowledge about the regulation of the platelet fibrinogen receptor, may be partially responsible for this therapeutic failure. Other compounds with improved pharmacokinetic properties are currently in clinical development. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S117 / S124
页数:8
相关论文
共 17 条
[1]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[2]  
Cannon CP, 1998, CIRCULATION, V97, P340
[3]   Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial [J].
Cannon, CP ;
McCabe, CH ;
Wilcox, RG ;
Langer, A ;
Caspi, A ;
Berink, P ;
Lopez-Sendon, J ;
Toman, J ;
Charlesworth, A ;
Anders, RJ ;
Alexander, JC ;
Skene, A ;
Braunwald, E .
CIRCULATION, 2000, 102 (02) :149-156
[4]  
DARIUS H, 1998, HAEMOSTASEOLOGIE, V18, P171
[5]   Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease [J].
Harrington, RA ;
Armstrong, PW ;
Graffagnino, C ;
Van de Werf, F ;
Kereiakes, DJ ;
Sigmon, KN ;
Card, T ;
Joseph, DM ;
Samuels, R ;
Granett, J ;
Chan, R ;
Califf, RM ;
Topol, EJ .
CIRCULATION, 2000, 102 (07) :728-735
[6]   Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban - Results of a multicenter, placebo-controlled, randomized trial [J].
Kereiakes, DJ ;
Kleiman, NS ;
Ferguson, JJ ;
Masud, Z ;
Broderick, TM ;
Abbottsmith, CW ;
Runyon, JP ;
Anderson, LC ;
Anders, RJ ;
Dreiling, RJ ;
Hantsbarger, GL ;
Bryzinski, B ;
Topol, EJ .
CIRCULATION, 1998, 98 (13) :1268-1278
[7]   Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment [J].
Kereiakes, DJ ;
Kleiman, N ;
Ferguson, JJ ;
Runyon, JP ;
Broderick, TM ;
Higby, NA ;
Martin, LH ;
Hantsbarger, G ;
McDonald, S ;
Anders, RJ .
CIRCULATION, 1997, 96 (04) :1117-1121
[9]   Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. [J].
O'Neill, WW ;
Serruys, P ;
Knudtson, M ;
van Es, GA ;
Timmis, GC ;
van der Zwaan, C ;
Kleiman, J ;
Gong, JJ ;
Roecker, EB ;
Dreiling, R ;
Alexander, J ;
Anders, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) :1316-1324
[10]   ANTIPLATELET DRUGS - A COMPARATIVE REVIEW [J].
SCHROR, K .
DRUGS, 1995, 50 (01) :7-28